Literature DB >> 28399388

Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary.

Davendra P S Sohal1, Pamela B Mangu1, Daniel Laheru1.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 28399388     DOI： 10.1200/JOP.2016.017368

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


× No keyword cloud information.
  11 in total

1.  A Randomized, Placebo-Controlled, Double-Blind Study of Minocycline for Reducing the Symptom Burden Experienced by Patients With Advanced Pancreatic Cancer.

Authors:  Mona Kamal; Xin Shelley Wang; Qiuling Shi; Tito Mendoza; Araceli Garcia-Gonzalez; Raza H Bokhari; Charles S Cleeland; David R Fogelman
Journal:  J Pain Symptom Manage       Date:  2020-01-24       Impact factor: 3.612

2.  Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX.

Authors:  Timothy J Vreeland; Florencia McAllister; Sanaz Javadi; Laura R Prakash; David R Fogelman; Linus Ho; Gauri Varadhachary; Thomas A Aloia; Jean-Nicolas Vauthey; Jeffrey E Lee; Michael P Kim; Matthew H G Katz; Ching-Wei D Tzeng
Journal:  Pancreas       Date:  2019-07       Impact factor: 3.327

3.  Nab-paclitaxel plus S-1 with or without PD-1 inhibitor in pancreatic ductal adenocarcinoma with only hepatic metastases: a retrospective cohort study.

Authors:  Qu Liu; Guodong Zhao; Xiuping Zhang; Nan Jiang; Zhiming Zhao; Yang Wang; Shuai Xu; Lin Zhu; Wan Yee Lau; Guanghai Dai; Rong Liu
Journal:  Langenbecks Arch Surg       Date:  2021-09-14       Impact factor: 2.895

4.  Calcium channel blockers potentiate gemcitabine chemotherapy  in pancreatic cancer.

Authors:  Daniel R Principe; Alexandre F Aissa; Sandeep Kumar; Thao N D Pham; Patrick W Underwood; Rakesh Nair; Rong Ke; Basabi Rana; Jose G Trevino; Hidayatullah G Munshi; Elizaveta V Benevolenskaya; Ajay Rana
Journal:  Proc Natl Acad Sci U S A       Date:  2022-04-27       Impact factor: 12.779

Review 5.  The prognostic value of B7-H4 in pancreatic cancer: Systematic review and meta-analysis.

Authors:  Xin Chen; Lianyuan Tao; Chunhui Yuan; Dianrong Xiu
Journal:  Medicine (Baltimore)       Date:  2018-03       Impact factor: 1.889

6.  Inhibition of JAK2/STAT3 signaling pathway by panaxadiol limits the progression of pancreatic cancer.

Authors:  Xuhui Fan; Haotian Fu; Ni Xie; Hangcheng Guo; Tiantian Fu; Yunfeng Shan
Journal:  Aging (Albany NY)       Date:  2021-10-08       Impact factor: 5.682

7.  Nomogram for Predicting the Prognoses of Patients With Pancreatic Head Cancer After Pancreaticoduodenectomy: A Population-Based Study on SEER Data.

Authors:  Wei Zhang; Lin Xu; Xu Che
Journal:  Front Oncol       Date:  2021-11-04       Impact factor: 6.244

Review 8.  The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives.

Authors:  Shun Wang; Yan Zheng; Feng Yang; Le Zhu; Xiao-Qiang Zhu; Zhe-Fang Wang; Xiao-Lin Wu; Cheng-Hui Zhou; Jia-Yan Yan; Bei-Yuan Hu; Bo Kong; De-Liang Fu; Christiane Bruns; Yue Zhao; Lun-Xiu Qin; Qiong-Zhu Dong
Journal:  Signal Transduct Target Ther       Date:  2021-07-05

9.  Can Elderly Patients With Pancreatic Cancer Gain Survival Advantages Through More Radical Surgeries? A SEER-Based Analysis.

Authors:  Danna Xie; Baolin Qian; Jing Yang; Xinya Peng; Yinghua Li; Teng Hu; Simin Lu; Xiaojing Chen; Yunwei Han
Journal:  Front Oncol       Date:  2020-10-29       Impact factor: 6.244

Review 10.  The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy.

Authors:  Daniel R Principe; Patrick W Underwood; Murray Korc; Jose G Trevino; Hidayatullah G Munshi; Ajay Rana
Journal:  Front Oncol       Date:  2021-07-15       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.